Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology.

Authors:
Rosa Giuliani
Rosa Giuliani
Jules Bordet Institute
Belgium
Josep Tabernero
Josep Tabernero
Vall d'Hebron University Hospital and Institute of Oncology (VHIO)
Spain
Fatima Cardoso
Fatima Cardoso
Jules Bordet Institute
Belgium
Malvika Vyas
Malvika Vyas
European Society for Medical Oncology

ESMO Open 2019 6;4(2):e000460. Epub 2019 Mar 6.

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Background: Biosimilars can potentially improve the sustainability of cancer care; however, uptake is sometimes limited by safety concerns and a lack of understanding of the concept of extrapolation. The European Society for Medical Oncology (ESMO) conducted a survey to assess the current level of knowledge, understanding and comfort of use of biosimilars among prescribers specialised in oncology.

Methods: A 19-question survey was developed using the SurveyMonkey online platform (https://www.surveymonkey.com/). Data collection occurred between September and October 2017 and included paper and online responses.

Results: Overall, 393 responses were received from prescribers. Overall, 49.0% of prescribers use biosimilars in clinical practice and most (79.2%) rate their general knowledge of biosimilars as average to very high. Potential increased risk of immunogenicity remains a significant concern of switching. Gaps in knowledge identified by the survey include biosimilar development, clinical trial design and endpoint selection, and requirements for extrapolation, which should form the focus of future educational initiatives. A substantial demand remains for further educational activities with equal preference for online and face-to-face initiatives. A higher rate of biosimilar use (56.3% vs 46.5%), knowledge of biosimilar development and trial design, and comfort with extrapolation, but a lower knowledge of European Medicines Agency definitions, was found among prescribers from Asia-Pacific versus those from Europe.

Conclusion: Encouraging levels of prescriber use and general knowledge of biosimilars were found, but a substantial need for further education remains. Efforts should be made worldwide to align terms, definitions and guidelines for the development and approval of biosimilars.

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2018-000460DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435239PMC
March 2019
2 Reads

Publication Analysis

Top Keywords

knowledge biosimilars
12
society medical
8
biosimilar development
8
trial design
8
european society
8
general knowledge
8
medical oncology
8
knowledge
7
biosimilars
6
comfort extrapolation
4
immunogenicity remains
4
biosimilars average
4
rate general
4
792% rate
4
european medicines
4
practice 792%
4
risk immunogenicity
4
lower knowledge
4
increased risk
4
high potential
4

Similar Publications